FYC: Small Growth ETF With High Fees But Compelling Results

First Trust Small Cap Growth AlphaDEX Fund ETF (FYC) offers diversified small-cap growth exposure, with 25.2% in healthcare and 21.2% in industrials, reducing single-name risk. The fund has outperformed the S&P SmallCap 600 Index and key small-cap growth ETF competitors despite a relatively high 0.70% expense ratio. Overall, the piece highlights solid relative performance and portfolio construction rather than a major market catalyst.

Analysis

The key edge here is not the basket itself, but the systematic selection effect: this type of rules-based small-cap growth exposure tends to overweight improving fundamentals before they show up in index committee revisions. That creates a delayed but repeatable source of alpha versus plain-cap-weighted small-cap exposure, especially when breadth is narrow and active managers are crowded into the same “quality growth” subset. The diversification also matters operationally: with low single-name dependence, the fund can keep outperforming through idiosyncratic earnings misses that would otherwise derail a more concentrated vehicle.

The second-order winner is not just the ETF holder base, but underlying second-tier companies that benefit from persistent buy-side sponsorship without needing index inclusion to rerate. The losers are higher-fee peers that rely on similar factor exposure but cannot justify the drag once performance differentials widen; that fee gap becomes more painful in choppy tapes where tracking error is tolerated only if the product wins consistently. If this relative outperformance persists for another 1-2 quarters, expect incremental flow migration from passive small-cap growth benchmarks into systematic active-like ETFs, reinforcing the trend through mechanically higher demand for the same mid-quality, improving names.

The main risk is regime reversal: small-cap growth leadership is fragile if rates back up, credit spreads widen, or economic data rolls over enough to penalize balance-sheet-sensitive businesses. Because the strategy is rules-based, it can also be slow to adapt at turning points, meaning the fund could remain exposed to the wrong factor mix for several weeks after the macro backdrop changes. The consensus may be underestimating how much of the recent outperformance is a function of style-cycle timing rather than permanent skill; if breadth narrows again, the same concentration in healthcare and industrials could become a headwind instead of a shield.

Key Decisions for Investors

• Go long FYC vs. IWO in a 3-6 month pair trade: thesis is systematic stock selection plus lower concentration risk should continue to outperform higher-beta small-cap growth, with a reasonable target of 200-400 bps alpha if the style backdrop remains benign.
• Use FYC as a tactical vehicle to express a small-cap growth rebound over the next 1-2 quarters, but cap position size: the edge is real, yet vulnerable to a rates-led reversal that can compress the whole factor basket quickly.
• Fade expensive, similar-factor ETF peers on relative performance: short the highest-fee small-cap growth wrapper against FYC if flow data confirms continued rotation toward cheaper systematic exposure.
• If rates spike or credit spreads widen materially, reduce exposure promptly; the risk-reward shifts fast because the underlying holdings are typically the first to de-rate when financing conditions tighten.